Clear Search

Showing 2 results for “disease activity” published 2025.

June 2025

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther 2025;27(1):116

Highlighting the importance of early belimumab initiation in SLE, patients with shorter disease duration achieve more substantial improvements in disease activity with early belimumab treatment.

more…

March 2025

Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials

Rheumatol, 2025. Epub ahead of print. DOI: 10.1093/rheumatology/keaf145

Grosso et al. conducted a post-hoc analysis of five phase III trials, including 3086 patients, to evaluate the efficacy of belimumab in improving mucocutaneous manifestations of SLE. The results demonstrated that belimumab significantly improved disease activity as measured by the mcBILAG and mcSLEDAI-2K indices compared with placebo and reduced flare rates in patients with high disease activity and serological positivity.

more…